A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector.

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Active vaccination using viral vectors often yields limited anti-tumor protection and requires multiple doses.
• Acute viral vectors elicit strong CD8 T cell responses but may not be ideal for long-term immunity.

Purpose of the Study:

• To investigate the efficacy of persistent viral vectors for anti-tumor immunity compared to acute viral vectors.
• To challenge the notion that T cell exhaustion in persistent infections precludes their use in cancer vaccines.

Main Methods:

• Utilized a persistent gammaherpesvirus vector and a non-persistent mutant of the same virus.
• Evaluated the anti-tumor protection conferred by each vector against melanoma development.

Main Results:

• The persistent gammaherpesvirus vector demonstrated superior protection against melanoma compared to the non-persistent mutant.
• CD8 T cell responses in low-load persistent infections remain functional and may be advantageous for sustained anti-tumor immunity.

Conclusions:

• Persistent viral vectors, particularly those derived from gammaherpesviruses, may offer enhanced and more durable anti-tumor protection than acute viral vectors.
• The findings suggest a paradigm shift in viral vector vaccine design, favoring persistent viruses for improved cancer immunotherapy.